Compare RCG & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | LEXX |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 14.5M |
| IPO Year | N/A | N/A |
| Metric | RCG | LEXX |
|---|---|---|
| Price | $2.57 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 5.9K | ★ 405.3K |
| Earning Date | 01-01-0001 | 01-09-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $1.52 | $0.48 |
| 52 Week High | $1.90 | $2.43 |
| Indicator | RCG | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 33.25 |
| Support Level | $2.53 | $0.48 |
| Resistance Level | $2.65 | $0.70 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 100.00 | 15.07 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.